Thyrocare Technologies Limited has informed the Exchange about Investor Presentation
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Thyrocare reported strong Q4FY26 results with consolidated revenue of Rs 224 Cr, up 20% YoY, and Reported EBITDA of Rs 75 Cr, up 31% YoY. For the full year FY26, consolidated revenue grew 21% to Rs 829 Cr while EBITDA surged 38% to Rs 262 Cr. PAT more than doubled in Q4 (up 128% YoY to Rs 49 Cr) and grew 81% for FY26 (Rs 163 Cr). EBITDA margins expanded significantly — Q4FY26 margin was 34% versus 31% in Q4FY25, and FY26 margin was 32% versus 28% in FY25. The franchisee network reached a record ~10,800 quarterly active franchisees, up 15% YoY, with tests conducted rising 23% to 209.6 Mn. Tanzania operations were fully consolidated as a subsidiary during the year. The company also onboarded Madhuri Dixit as brand ambassador and expanded its test menu to 1,275 tests.
The company delivered broad-based growth across revenue, margins, and network expansion, with PAT doubling and EBITDA margins expanding by 288 basis points year-over-year. Strong cash generation of Rs 213 Cr from operations and improved profitability signal operational leverage working well, which should be positive for the stock.